Anh Nguyen
Psychiatric/Mental Health · Chicago, ILNPI 1508437484
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 85.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $7,199 and has fallen 84.3% since, to $1,132 in 2025. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $190.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$8K
- Otsuka America Pharmaceutical, Inc.$441
- Alkermes, Inc.$150
- Johnson & Johnson$142
- Neurocrine Biosciences, Inc.$124
- AbbVie$123
- plus $274 from 4 others
What the payments were for
- Consulting fees$2,80032%
- Speaking & faculty fees$2,80032%
- Travel & lodging$97211%
- Food & beverage$2,19225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $7,510 |
| Otsuka America Pharmaceutical, Inc. | 8 | $441 |
| Alkermes, Inc. | 3 | $150 |
| Johnson & Johnson | 1 | $142 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| AbbVie | 1 | $123 |
| Lundbeck LLC | 6 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $104 |
| Indivior Inc. | 2 | $38 |
| Atricure, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,764 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 13 | $267 |
| Olanzapine | 19 | $161 |
| Hydroxyzine Hcl | 19 | $134 |
| Trazodone Hcl | 14 | $34 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Julie CarbrayChicago$36K
- Abigail HamiltonChicago$14K
- Sherann IvyChicago$8K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.